Semprini A.E.Savasi V.Hollander L.Tanzi E.Fiore S.Newell M.-L.Pembrey L.Zanetti A.Coll O.Numazaki K.Fujikawa T.Chiba S.Hari P.Prasad C.G.K.Lankipalli R.HO-HSIUNG LINJIA-HORNG KAODING-SHINN CHENGibb D.M.Dunn D.T.Goodall R.L.2021-09-042021-09-0420010140-6736https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035852493&doi=10.1016%2fS0140-6736%2800%2903555-8&partnerID=40&md5=e80aa60dab5f8bac813a9f9593fd5333https://scholars.lib.ntu.edu.tw/handle/123456789/582268[SDGs]SDG3virus RNA; blood transfusion; clinical trial; cytomegalovirus infection; disease course; drug abuse; female; fetus; hepatitis C; Hepatitis C virus; human; Human immunodeficiency virus infection; letter; multicenter study; nonhuman; priority journal; vertical transmission; viremia; virus hepatitis; virus load; virus transmission; disease transmission; hepatitis C; pregnancy; pregnancy complication; note; Disease Transmission, Vertical; Female; Hepatitis C; Humans; Pregnancy; Pregnancy Complications, Infectiousletter10.1016/S0140-6736(00)03555-8111974182-s2.0-0035852493